We further determined the prognostic significance of B3GALT5 expression in both tumor and adjacent non-tumor tissue among different subsets of breast cancer patients, including stages I–II (n = 158), stages I–II and luminal A (n = 68), and stages I–II and luminal B (n = 52), as shown in the Kaplan–Meier analysis of RFS (Supplementary Fig. S4) and OS (Supplementary Fig. S5). The gene discussed is B3GALT5; the disease is breast cancer.